Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?  by De Vriese, An S. et al.
Kidney International, Vol. 61 (2002), pp. 1199–1209
PERSPECTIVES IN RENAL MEDICINE
Is folate a promising agent in the prevention and treatment of
cardiovascular disease in patients with renal failure?
AN S. DE VRIESE, FRANCIS VERBEKE, BIEKE F. SCHRIJVERS, and NORBERT H. LAMEIRE
Renal Unit, University Hospital Gent, Gent, Belgium
need to be demonstrated in randomized trials. Such trials areIs folate a promising agent in the prevention and treatment of
currently underway in patients with normal renal function atcardiovascular disease in patients with renal failure? Manage-
high risk for cardiovascular disease, and one trial has recentlyment of the conventional cardiovascular risk factors is insuffi-
been initiated in stable renal transplant recipients.cient to prevent the dramatic increase in atherosclerotic cardio-
vascular morbidity and mortality in patients with renal failure.
Folate recently received attention as a potential alternative treat-
ment option to decrease the excess cardiovascular risk in the Atherothrombotic cardiovascular disease remains the
uremic population. Folate administration is the principal treat- leading cause of morbidity and mortality in patients with
ment modality for hyperhomocysteinemia. Hyperhomocystein-
renal failure, regardless of whether they are in the preter-emia is prevalent in more than 85% of patients with end-stage
minal stage, on maintenance dialysis or have received arenal disease (ESRD) and is independently associated with in-
kidney transplant [1]. Despite the high prevalence ofcreased odds for atherosclerotic cardiovascular disease. Several
attempts have been made to normalize homocysteine levels in established cardiovascular risk factors in renal failure
uremic patients with folate-based vitamin regimens. Although patients, the predictive value of these risk factors for
supraphysiologic doses of folic acid afford greater reductions in cardiovascular outcome is not as strong as in the general
homocysteine levels than standard doses, the response to treat-
population. Management of diabetes, hypertension orment is generally only partial and the large majority of ESRD
dyslipidemia is often inadequate and appears insufficientpatients have residual hyperhomocysteinemia. Several defects
to prevent the excess cardiovascular incidents in patientsin folate metabolism have been described in uremia, which may
explain the relative folate resistance in patients with renal fail- with renal failure [1]. Accordingly, there is a compelling
ure, but their clinical relevance remains uncertain. It appears need for adjunctive therapies that have an aspecific or
unlikely that the hyperhomocysteinemia in ESRD can be cured broad beneficial action on endothelial cell metabolism
solely with folic acid supplements, since folate does not affect
or target non-conventional cardiovascular risk factors.the prolonged plasma elimination of homocysteine, which is the
Folate has recently received attention as a potentiallyprimary defect in homocysteine metabolism in uremia. Folate re-
promising tool in the prevention and treatment of cardio-stores endothelial dysfunction, associated with hyperlipidemia,
diabetes and hyperhomocysteinemia. The beneficial effect ap- vascular disease associated with diverse risk factors [2].
pears to be independent of its homocysteine-lowering capacity Folate derivatives feature in a variety of biosynthetic
and is possibly related to an improved bioavailability of nitric pathways that are critical for purine and pyrimidine me-
oxide. However, folate has failed to improve endothelial dys-
tabolism and cell replication [3]. In addition, folate playsfunction in uremic patients. In the ESRD population, multiple
an essential role in homocysteine metabolism (Fig. 1)metabolic and hemodynamic abnormalities adversely affect en-
and is well-known as the primary treatment modality fordothelial function. In addition, irreversible structural vascular
disease already may be present. Folate should, therefore, prob- hyperhomocysteinemia. Hyperhomocysteinemia is prev-
ably be an integral part of an “endothelial protective regimen,” alent in more than 85% of patients with end-stage renal
consisting of lipid-lowering agents, antihypertensives and anti- disease (ESRD). In the past decade, homocysteine has
oxidant vitamins and started very early in patients with renal
been widely recognized as an independent predictor offailure. Before large-scale folate administration can be recom-
cardiovascular disease, not only in the general popula-mended, effects on hard endpoints of cardiovascular disease
tion, but also in renal failure patients. Even a total plasma
homocysteine (tHcy) level in the top fifth of the distribu-
tion curve is significantly correlated with an increasedKey words: cardiovascular risk, endothelial dysfunction, folate, folic
acid, homocysteine, hyperhomocysteinemia. risk for coronary artery disease, stroke, peripheral artery
disease and venous thrombosis [4]. As a consequence,Received for publication February 19, 2001
diverse folate-based regimens were tested for their po-and in revised form August 28, 2001
Accepted for publication September 10, 2001 tential to lower tHcy levels in renal failure. However, in
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Fig. 1. Folate and homocysteine metabolism. Dietary folates occur as polyglutamates (PG) that are deconjugated in the intestinal wall to mono-
glutamates (MG). These compounds are reduced to dihydrofolate (DHF) and subsequently to tetrahydrofolate (THF). THF is converted to 5,10-
methylenetetrahydrofolate (5,10-MeTHF), which is irreversibly reduced to 5-methyltetrahydrofolate (5-MTHF) by the enzyme 5,10-methylenetet-
rahydrofolate reductase (MTHFR). 5,10-MeTHF and 10-formyltetrahydrofolate (folinic acid, 10-CHO THF) are used in pyrimidine and purine
synthesis, respectively. 5-MTHF plays a central role in homocysteine metabolism. Methionine is converted to S-adenosyl methionine (SAM) and
then to S-adenosyl homocysteine (SAH), which is hydrolyzed to homocysteine and adenosine. Homocysteine is either remethylated back to
methionine or degraded in the transsulfuration pathway. Cystathionine  synthase (CS) is the main enzyme of the transsulfuration pathway and
requires vitamin B6 as a cofactor. Methionine synthase catalyzes remethylation of homocysteine and uses 5-MTHF as cosubstrate and vitamin B12
as a cofactor. An alternative remethylation route uses betaine as cosubstrate.
hyperhomocysteinemia in renal failure patients proves beneficial action of folate on endothelial cell metabolism,
independent of its homocysteine-lowering potential, isquite refractory to standard folate-containing B-vitamin
supplementation. discussed. Finally, the evidence (or the lack of evidence)
for an effect of folate supplementation on hard endpointsThe present communication addresses the evidence
for a potentially disturbed folate metabolism in uremia of cardiovascular disease is addressed.
that may be responsible for the apparent inefficiency of
FOLATE METABOLISM IN RENAL FAILUREfolate to normalize homocysteine status in patients with
renal failure. In addition, the extant intervention studies Patients with renal failure, and in particular those on
with folate in this patient population are reviewed, focus- dialysis, are at risk for deficiencies of the water-soluble
ing on different endpoints. First, the effects of different vitamins, as a result of restricted intake, impaired absorp-
folate regimens on tHcy levels are evaluated in predial- tion, uremia-induced alterations in metabolism and activ-
ysis patients, patients on maintenance dialysis and renal ity, losses during hemo- or peritoneal dialysis and treat-
transplant recipients, in order to define the optimal dose, ment with erythropoietin [5–8]. Whereas folate and
vitamin B12 deficiency may be somewhat less common,folate species and combination with other B vitamins
that achieves the maximal tHcy-lowering effect. Second, vitamin B6 deficiency occurs in the large majority of
unsupplemented patients on dialysis. Therefore, a vita-studies examining the influence of folate on endothelial
dysfunction as an intermediary endpoint for cardiovascu- min supplement including vitamin B6 10 mg/day, vitamin
B12 12 g/day and folic acid 1 mg/day has been recom-lar disease are reviewed. More in particular, the potential
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mended to optimize vitamin status in these patients [9]. FOLATE AND PLASMA HOMOCYSTEINE
LEVELS IN RENAL FAILURENevertheless, an inverse correlation between serum and/or
erythrocyte folate and tHcy levels has been reported Results of homocysteine-lowering intervention trials
even in subjects with normal vitamin status [10–17], al- A large number of studies have attempted to normal-
though other studies failed to confirm these findings ize tHcy levels in renal failure patients with pharmaco-
[18–20]. logical folate supplementation (Table 1). The rationale
Diverse defects in folate metabolism have been dem- behind this maneuver is that administration of supra-
onstrated in experimental and clinical uremia. The intes- physiologic doses of folate enhances the activity of the
tinal absorption of 5-methyltetrahydrofolate (5-MTHF) homocysteine remethylation pathway, since folate serves
was lower in uremic rats than in control rats, a difference as the cosubstrate in this pathway, thereby consuming
that could be attributed to the uremic environment the excess homocysteine. In addition, as outlined above,
rather than to an acquired intrinsic defect of the entero- it was assumed that defects in folate metabolism in ure-
cytes [21]. The activity of folate conjugase, an enzyme mia required the administration of high doses of folate.
that splits polyglutamate forms of folate into monogluta- As initial studies with pharmacological folate supple-
mates and is believed to play a vital role in the absorption mentation were rather disappointing, it was thought that
and metabolism of folates, was low in predialysis blood even higher doses were required. Consequently, much
samples [22]. The activity was restored to normal after effort has been spent determining the optimal dose, fo-
a hemodialysis session, suggesting the presence of an late species and combination with other B vitamins that
inhibitor of the enzyme in uremic plasma [22]. The trans- may normalize tHcy in renal failure patients.
port of methotrexate in Ehrlich ascites tumor cells, used Depending on whether or not patients are already
treated with multivitamin preparations containing folicas a model for transmembrane transport of folates, was
acid, pyridoxine and cobalamin, the mean tHcy level ininhibited by uremic serum or ultrafiltrate [23]. In addi-
patients with ESRD varies between 20 to 50 mol/Ltion, the incorporation of [14C] 5-MTHF into nucleic
(Table 1A). In subjects with preterminal renal failureacids and proteins was blocked by anions retained in
and in renal transplant recipients, mean tHcy levels areuremia [23], suggesting that the uptake and utilization
generally between 15 and 20 mol/L, depending on theof folate may be impaired in uremic patients. Finally, the
degree of renal failure (Table 1 B, C). As compared withlevels of free blood folates available for transmembrane
no treatment [17, 19], placebo treatment [20, 32, 37] ortransport may be reduced in renal failure, due to an
standard folate doses (the recommended daily allowanceincreased binding to serum proteins [23, 24].
for folate is 0.4 mg/g) [36], supraphysiologic doses of folicTaken together, these observations gave rise to the spec-
acid afford significantly greater reductions in tHcy levels.ulation that renal failure is characterized by relative folate
Generally, a mean tHcy reduction of about 30% is ob-deficiency. Uremic patients may not reach adequate in-
tained, with exceptions reporting a decrease of 60 to 70%tracellular levels of 5-MTHF (the biologically active form
[25, 30]. Several studies found close correlations betweenof folate), even though their total serum folate levels,
pretreatment tHcy and the response to therapy [19, 20,as measured by standard assays that do not distinguish
27, 30, 35]. In other words, patients who manifest the
between the different folate species, may be normal [25].
highest tHcy concentrations derive the largest benefit from
Therefore, it was proposed that supraphysiologic doses treatment. However, even after treatment, most patients
of folic acid are required to normalize homocysteine levels with ESRD have residual hyperhomocysteinemia and only
in this patient population. In addition, some authors a limited number of subjects achieve normal levels. It
thought it desirable to administer the active form of should be noted that many of these studies used 14 to 16
folate intravenously, in order to circumvent or override mol/L as the upper limit of normal for tHcy, whereas it
the defects in folate absorption, glutamation and trans- has been demonstrated that levels of 12 to 14 mol/L
membrane transport [25]. The issue was recently clarified are already associated with an increased cardiovascular
by the finding of normal 5-MTHF fractions and gluta- risk [4]. When the currently accepted upper limit of nor-
mate chain length in serum and erythrocytes of hemodi- mal (12 mol/L) is used, virtually none of the patients
alysis patients [9]. After oral administration of either with ESRD obtained normal post-treatment tHcy levels.
5-MTHF or folic acid, a substantial increase in 5-MTHF Folate-containing regimens were generally more success-
was noted, which was similar in both treatment groups ful in predialysis patients [32–35]. In a non-controlled
[9]. This clinical study thus failed to find any evidence study, 69% of the patients obtained tHcy levels below
of defective folate metabolism in uremia. It should be 14 mol/L [33] and 20% fell below 12 mol/L in a ran-
noted, however, that the erythrocyte contents and distri- domized trial [32]. Similarly, renal transplant recipients
bution of folate species may not be representative of generally respond well to folate supplementation [36–39].
In one study, 65% of renal transplant recipients achievedthose of metabolically active folate-dependent tissues.
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tHcy levels below 12mol/L with high-dose multivitamin to homocysteine-lowering treatment appears desirable.
Betaine did not affect tHcy levels in ESRD patientstreatment [36].
Whereas it is accepted that supraphysiologic folate [16, 29, 41] and therefore should not be included in the
homocysteine-lowering regimens.doses are required for the treatment of hyperhomocys-
teinemia in subjects with renal failure, the exact dose An inverse correlation between tHcy levels and the
duration of folate administration has been reported, andthat has the optimal homocysteine-lowering capacity has
been the subject of continued debate. Whereas two ran- the authors suggested that some patients may require
longer periods of treatment to achieve normalization ofdomized trials in ESRD patients showed that 15 mg folic
acid conferred an additional 15 to 25% reduction in tHcy their tHcy [25]. These findings were not supported by
other studies where intermediary samples showed thatas compared to 1 mg folic acid [9, 31], several other
studies found no benefit of very high folate doses. Doses the effect of folate administration was of rapid onset and
sustained [16, 29, 18, 27].up to 60 mg/day were not superior in lowering tHcy
concentrations than a dose of 15 mg/day [27]. Post-treat- In light of these collective data, the optimal homocys-
teine-lowering regimen in patients with renal failure ap-ment tHcy was similar in dialysis patients given either 1
or 5 mg/day folic acid [16, 29] and a switch to 15 mg/day pears to be a daily oral supplement of 1 to 5 mg folic
acid, combined with 6 to 12 g vitamin B12 and 10 to 50was not associated with a further decrease [16]. These
findings are in line with a recent study examining the g vitamin B6. There is no evidence that intravenous
administration is superior to oral administration. Onlyeffects of consecutive increments of the dose of folic acid
in hemodialysis patients [19]. The maximal homocys- in non-compliant patients, as judged from a failure to
increase their vitamin levels, would systemic administra-teine-lowering response to folic acid was already ob-
tained at an oral dose of 15 mg/week. Interestingly, eryth- tion be the preferred way. Such a treatment regimen will
normalize tHcy in many renal transplant recipients androcyte folate levels approached saturation at this dose,
whereas serum folate levels continued to rise linearly subjects with preterminal renal failure, but the large ma-
jority of patients with ESRD will have substantial resid-along with the folate dose [19]. In accordance, an equiva-
lent rise in erythrocyte and serum folate levels was ob- ual hyperhomocysteinemia. Further increasing the dose
of folic acid does not afford a greater reduction of tHcyserved with doses up to 15 mg/week [13], whereas serum
folate levels increased in excess of erythrocyte levels in this population and is therefore not recommended.
after a dose of 10 mg/day [20]. Restricted intracellular
Can folate normalize tHcy in patients withexcess thus appears to limit the efficiency of folate. After
renal failure?treatment with folate supplements, the correlation be-
tween serum folate and tHcy is lost [13, 40]. Taken to- Whereas a comprehensive discussion of all reports
addressing the etiology of hyperhomocysteinemia in re-gether, these data suggest that there is an upper limit in
folate status above which no further enhancement of the nal failure is beyond the scope and space limitations of
this article, a short review may be required to addressremethylation pathway and reduction in tHcy levels can
be achieved. The optimal dose of folic acid in renal the cause of the folate resistance in ESRD. Any form
of hyperhomocysteinemia is a steady-state condition,failure may be in the range of 1 to 5 mg/day.
Although a dramatic effect of the reduced folate spe- characterized by either an increased cellular homocys-
teine export and/or an impaired elimination of homocys-cies folinic acid [25] and 5-MTHF [30] was observed
in two non-controlled studies, subsequent randomized teine from the plasma compartment. Folate- and coba-
lamin-deficient subjects have a normal plasma clearancetrials provided no evidence that these folate species af-
ford a greater reduction in tHcy levels than standard of homocysteine before or after vitamin supplementa-
tion, indicating that their hyperhomocysteinemia is re-folic acid [9, 26].
Whereas high-dose vitamin B6 supplementation had lated to an increased net efflux from tissues to plasma
[42]. In contrast, the hyperhomocysteinemia in patientsno independent effect on fasting tHcy in several non-
controlled studies [17, 34, 39], a randomized trial found with renal failure is due to a marked reduction of the
homocysteine clearance from plasma [43]. Whether thisa significant reduction of post-methionine tHcy with vita-
min B6 treatment [37]. As a large proportion of uremic reduced clearance results from the loss of normal intra-
renal metabolism, the adverse effects of uremic toxinspatients additionally have vitamin B6 deficiency, inclu-
sion of pyridoxine in homocysteine-lowering regimens on extrarenal metabolism, or a combination of these
factors remains conjectural [44, 45]. Whatever the causeis recommended. No additional benefit of vitamin B12
administration was found in a small group of renal trans- of the impaired plasma clearance, it is not enhanced
by folic acid administration [43], even though folic acidplant recipients [39]. In contrast, vitamin B12 lowered
tHcy with 35% in dialysis patients with low cobalamin lowers tHcy levels. These findings are particularly well
suited to explain why the hyperhomocysteinemia inlevels [14]. As the presence of a suboptimal vitamin B12
status in ESRD is not rare, routine addition of vitamin B12 ESRD cannot be cured solely with folic acid supple-
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ments. Folic acid enhances the remethylation of homo- nine load test in healthy volunteers without affecting the
rise in plasma tHcy levels [56]. Parallel in vitro studiescysteine in the tissues and, by virtue of this action, lowers
the efflux into the plasma compartment, but does not were conducted to provide a rationale for the vasculo-
protective effects of folate, independent of homocysteineaffect the primary defect in homocysteine metabolism
in renal failure, that is, the prolonged plasma elimination. metabolism. In physiological conditions, endothelial ni-
tric oxide (NO) synthase predominantly produces NO,In patients with mild-to-moderate renal failure, the ac-
celeration of the remethylation pathway in the tissues but under pathological circumstances the production shifts
from NO to superoxide, leading to an impaired bio-and resulting decreased homocysteine export may be
sufficiently large to override the defect in homocysteine availability of NO [57]. 5-MTHF affects the enzyme in
a dual manner: it enhances the production of NO andelimination and obtain new steady state levels in the
normal range. In the large majority of patients with reduces the generation of superoxide anions [57]. In ad-
dition, 5-MTHF has a direct superoxide scavenging activ-ESRD, however, the new steady state levels will remain
elevated. ity, although weaker than vitamin C [57]. It thus appears
that folate improves the bioavailability of NO by pre-This new level of understanding hopefully sets the
stage for the search for alternative therapies that may venting its oxidative degradation. An increased availabil-
ity of bioactive NO supports the function of the endothe-normalize tHcy in ESRD. One potential approach would
be to augment the dialysis-related removal of tHcy. In lium and may protect the vasculature against atherogenic
influences.a randomized trial controlling for B vitamin intake, no
difference in tHcy levels was found in patients dialyzed Although vascular dysfunction in uremia is character-
ized by increased oxidative stress and an impaired bio-with a F8 or a F80 dialyzer [46]. In contrast, patients
randomized to a F500S or a Tricea 150G dialyzer had availability of NO [58], the effects of folate on endothe-
lial dysfunction in patients with renal failure have beensignificantly lower tHcy levels as compared to subjects
treated with a F60 dialyzer, although tHcy remained disappointing (Table 2). In spite of a 23% decrease of
tHcy, no change of endothelial-derived proteins or mark-elevated in all groups [47].
ers of endothelium-dependent vascular reactivity was
FOLATE AND ENDOTHELIAL DYSFUNCTION observed in hemodialysis patients treated with oral folic
acid [20]. Similarly, neither endothelial markers nor en-Endothelial dysfunction has been demonstrated in
subjects with preterminal renal failure, in patients on dothelium-dependent vasodilation improved after long-
term treatment of hemodialysis patients with folic acidhemodialysis and peritoneal dialysis and in renal trans-
plant recipients, by the presence of impaired endothe- [16]. When patients with antecedent cardiovascular dis-
ease and smokers were excluded, a weak trend for im-lium-dependent vasodilation or by increased circulating
levels of endothelium-derived proteins [29, 48–50]. The provement of endothelium-dependent vasodilation was
found [16]. Even though a sustained reduction of tHcyfinding of endothelial dysfunction represents a window
of opportunity, as it identifies patients at risk for devel- was obtained, folic acid treatment did not improve endo-
thelial function in peritoneal dialysis patients [29]. Itoping clinical vascular complications before the advent
of structural vascular disease [51]. Improvement of endo- should be noted that the latter two studies did not include
a placebo arm. It is therefore unknown whether endothe-thelial dysfunction is therefore considered a surrogate
endpoint for the reduction in cardiovascular morbidity lial function spontaneously deteriorated during the treat-
ment period, thereby masking a potential beneficial ef-and mortality.
Recently, several studies reported that folate may re- fect. Finally, a randomized trial found no improvement
in endothelium-dependent vasodilation and plasma vonstore endothelial dysfunction associated with various risk
factors (Table 2). The effects appeared to be indepen- Willebrand concentration in predialysis patients after
folic acid, although treatment was associated with a mod-dent of the homocysteine-lowering capacity of folate.
Both a single intravenous bolus of 5-MTHF [52] and four est decrease in tHcy from 17.7 to 15.1 mol/L [32].
Several explanations for this apparent failure of folateweeks of oral treatment with folic acid [53] completely
restored the impaired endothelium-dependent vasodila- to improve endothelial function in renal failure patients
can be forwarded. First, if one assumes that the endothe-tion in the forearm circulation of patients with familial
hypercholesterolemia. An acute fat load in healthy vol- lial dysfunction in renal failure patients is related to
hyperhomocysteinemia, no efficient therapy was providedunteers was associated with an increased excretion of
oxidative end products and a decreased endothelium- by the administration of folate. In all studies, substantial
residual hyperhomocysteinemia was present after treat-dependent vasodilation, both of which were prevented
by oral treatment with folic acid [54]. Systemic adminis- ment [16, 20, 29, 32]. Since even mild elevations of tHcy
are associated with impaired endothelium-dependent va-tration of 5-MTHF restored the endothelial dysfunction
in the renal microcirculation of diabetic rats [55]. Finally, sodilation [59], a restoration of endothelial dysfunction
could hardly be expected. Second, there are a host offolate normalized endothelial function during a methio-
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threats to the endothelium in subjects with renal failure cance of these findings remains unclear. To confirm a
causal relation between low folate status and cardiovas-besides hyperhomocysteinemia. This was clearly illus-
trated by the absence of a correlation between endothe- cular disease, definitive data from randomized, placebo-
controlled trials of the effect of folate-containing supple-lial function parameters and tHcy levels at baseline [16].
It was not specified to what extent prevalent risk factors ments on the incidence of cardiovascular events are re-
quired. Several large-scale clinical trials are currentlywith deleterious effects on the endothelium, including
hypertension, dyslipidemia, diabetes and smoking, were planned or underway, examining the effects of folate-
based regimens in subjects with normal renal functionadequately treated in these studies. In addition, several
renal failure-specific factors that are known to adversely and prior vascular disease or at high risk for vascular
events [69]. Recently, a large randomized placebo-con-affect endothelial function may be difficult to manage,
including oxidative stress caused by repeated hemodialy- trolled trial studying the effect of tHcy-lowering therapy
on hard cardiovascular end points in 4000 stable renalsis procedures and high circulating levels of uremic toxins
that are endogenous inhibitors of NO synthase [49, 60]. transplant recipients has been initiated under the aegis
of the National Institute of Diabetes and Digestive andThird, patients with ESRD already may have suffered
irreversible structural vascular disease when they were Kidney Diseases.
included in these studies. In this respect, radiologic evi-
SAFETY OF FOLATE ADMINISTRATIONdence of aortic calcifications was present in 70% and
small vessel calcifications of the hand were found in 28% Several authors have performed a systematic assess-
ment of the potential adverse effects of pharmacologicof dialysis patients treated with folate in one study [20].
Therapy may need to be started early in the preterminal folate supplements in uremic patients and found no ap-
parent evidence for toxicity [17, 25, 27, 31], suggestingstage of renal failure, when patients only have functional
alterations of the endothelium without structural lesions. that high doses of folic acid are well tolerated and safe
in this population. The most feared side effect of folicFinally, the currently used parameters to evaluate endo-
thelial function may not be appropriate in renal failure acid is its ability to mask the hematologic manifestations
patients. Whereas the presence of impaired endothe- of vitamin B12 deficiency, while the neurological compli-
lium-dependent vasodilation in the coronary circulation cations progress [70]. While an informal survey suggested
is predictive for incident cardiovascular events [51], no that this complication is extremely rare [70], routine mea-
such evidence exists for endothelial dysfunction in the surement of vitamin B12 concentrations and inclusion of
brachial artery or forearm circulation. Studies of endo- vitamin B12 in the supplements should completely elimi-
thelium-dependent vasodilation therefore need to be nate this risk. It should be kept in mind that high systemic
conducted in clinically more relevant vasculatures [61], doses of folate may reverse the effectiveness of anticon-
such as the coronary circulation. However, the invasive vulsants [70]. Whether folate compromises the therapeu-
nature of angiographic procedures precludes their rou- tic effects of inhibitors of dihydrofolate reductase, in-
tine use for this purpose. It is our task to develop non- cluding methotrexate, pyrimethamine, trimethoprim and
invasive tests that enable us to diagnose endothelial dys- triamterene, is unknown [70].
function early in the target organs of uremia, and to
evaluate the validity of these tests as surrogate endpoints
CONCLUSIONfor cardiovascular disease. Flow measurements with pos-
Although folate-containing regimens have succeededitron emission tomography or magnetic resonance im-
in consistently lowering tHcy levels in renal failure pa-aging appear to be an attractive tool in this respect [62].
tients, hyperhomocysteinemia persists in the large major-In conclusion, folate restores endothelial dysfunction
ity of subjects with ESRD, despite supranormal plasmaassociated with well-defined risk factors, probably through
and erythrocyte folate levels. It should be kept in mindan improvement of the bioavailability of NO. However,
that even mild hyperhomocysteinemia is associated withstudies in patients with renal failure have not provided
an increased risk for atherothrombotic cardiovascularevidence for a beneficial effect of folate on endothelial
disease. The modest success of the folate-based regimensdysfunction in these patients.
leaves us now poised to explore alternative treatment
FOLATE AND CARDIOVASCULAR options, in order to completely normalize tHcy levels in
MORBIDITY AND MORTALITY ESRD. A rational approach to the treatment of this
residual hyperhomocysteinemia rests heavily on progressSeveral studies found higher odds ratios for vascular
in the knowledge of the pathogenesis of impaired homo-disease in subjects with low folate levels [63–67]. Users
cysteine clearance in renal failure.of folate-containing vitamin supplements experience
Evidence has emerged for a broad beneficial actionsubstantial protection from vascular disease [4, 68]. How-
of folate on endothelial cell metabolism, independent ofever, since the use of vitamin preparations may be associ-
ated with other health-conscious behavior, the signifi- its role in homocysteine metabolism and possibly acting
De Vriese et al: Effects of folate in renal failure1208
12. Tamura T, Johnston KE, Bergman SM: Homocysteine and folatevia direct or indirect antioxidant effects. These studies
concentrations in blood from patients treated with hemodialysis.
clearly need confirmation from larger trials. Although J Am Soc Nephrol 7:2414–2418, 1996
successful in subjects with discrete cardiovascular risk 13. Dierkes J, Domrose U, Ambrosch A, et al: Response of hyperho-
mocysteinemia to folic acid supplementation in patients with end-factors, folate has failed to improve endothelial dysfunc-
stage renal disease. Clin Nephrol 51:108–115, 1999tion in patients with renal failure. The presence of multi- 14. Dierkes J, Domrose U, Ambrosch A, et al: Supplementation with
ple metabolic abnormalities with adverse effects on en- vitamin B12 decreases homocysteine and methylmalonic acid but
also serum folate in patients with end-stage renal disease. Metabo-dothelial function in renal failure may play a role in
lism 48:631–635, 1999this respect. In addition, irreversible endothelial damage 15. Suliman ME, Divino Filho JC, Barany P, et al: Effects of high-
already may have occurred by the time patients are con- dose folic acid and pyridoxine on plasma and erythrocyte sulfur
amino acids in hemodialysis patients. J Am Soc Nephrol 10:1287–sidered for treatment. Therefore, folate probably should
1296, 1999be an integral part of an “endothelial protective regi- 16. van Guldener C, Janssen MJ, Lambert J, et al: No change in
men” consisting of lipid-lowering agents, antihyperten- impaired endothelial function after long-term folic acid therapy
of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dialsives and antioxidant vitamins, and started very early in
Transplant 13:106–112, 1998patients with renal failure.
17. Arnadottir M, Brattstrom L, Simonsen O, et al: The effect of
Ultimately, the effect of folate on cardiovascular mor- high-dose pyridoxine and folic acid supplementation on serum lipid
and plasma homocysteine concentrations in dialysis patients. Clinbidity and mortality needs to be explored in large ran-
Nephrol 140:236–240, 1993domized trials. Such studies are currently in progress in
18. Tremblay R, Bonnardeaux A, Geadah D, et al: Hyperhomocys-
subjects with normal renal function and the results are teinemia in hemodialysis patients: Effects of 12-month supplemen-
tation with hydrosoluble vitamins. Kidney Int 58:851–858, 2000eagerly awaited. Recently, a trial has been initiated ex-
19. Arnadottir M, Gudnason V, Hultberg B: Treatment with differ-amining the effects of folate-based vitamin regimens on
ent doses of folic acid in haemodialysis patients: Effects on folate
hard cardiovascular endpoints in renal transplant recipi- distribution and aminothiol concentrations. Nephrol Dial Trans-
ents. In accordance with current official guidelines [71, 72], plant 15:524–528, 2000
20. Kunz K, Petitjean P, Lisri M, et al: Cardiovascular morbiditylarge-scale folate administration should be withheld,
and endothelial dysfunction in chronic haemodialysis patients: Ispending results from these trials. homocyst(e)ine the missing link? Nephrol Dial Transplant 14:1934–
1942, 1999
Reprint requests to An De Vriese, M.D., Ph.D., Renal Unit, AZ Sint- 21. Said HM, Vaziri ND, Kariger RK, Hollander D: IntestinalJan, Ruddershove 10, B-8000 Brugge, Belgium. absorption of 5-methyltetrahydrofolate in experimental uremia.E-mail: an.devriese@azbrugge.be
Acta Vitaminol Enzymol 6:339–346, 1984
22. Livant EJ, Tamura T, Johnston KE, et al: Plasma folate conjugase
activities and folate concentrations in patients receiving hemodialy-REFERENCES
sis. J Nutr Biochem 5:504–508, 1994
1. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic 23. Jennette JC, Goldman ID: Inhibition of the membrane trans-
of cardiovascular disease in chronic renal disease: What do we port of folates by anions retained in uremia. J Lab Clin Med 86:
know? What do we need to learn? Where do we go from here? 834–843, 1975
Am J Kidney Dis 32:853–905, 1998 24. Retief FP, Heyns AP, Oosthuizen M, Reenen OR: Aspects of
2. Verhaar MC, Rabelink TJ: Future for folates in cardiovascular folate metabolism in renal failure. Br J Haematol 36:405–415, 1977
disease. Eur J Clin Invest 29:657–658, 1999 25. Touam M, Zingraff J, Jungers P, et al: Effective correction of
3. Massy ZA: Reversal of hyperhomocyst(e)inaemia in chronic renal hyperhomocysteinemia in hemodialysis patients by intravenous
failure-is folic or folinic acid the answer? Nephrol Dial Transplant folinic acid and pyridoxine therapy. Kidney Int 56:2292–2296, 1999
14:2810–2812, 1999 26. Yango A, Shemin D, Hsu N, et al: Rapid communication: L-folinic
4. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine acid versus folic acid for the treatment of hyperhomocysteinemiaas a risk factor for vascular disease. The European Concerted in hemodialysis patients. Kidney Int 59:324–327, 2001Action Project. JAMA 277:1775–1781, 1997
27. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al: Effect5. Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic re-
of high dose folic acid therapy on hyperhomocysteinemia in hemo-nal failure and need for supplementation. Blood Purif 3:52–62, 1985
dialysis patients: Results of the Vienna multicenter study. J Am6. Descombes E, Hanck AB, Fellay G: Water soluble vitamins in
Soc Nephrol 11:1106–1116, 2000chronic hemodialysis patients and need for supplementation. Kid-
28. House AA, Donnelly JG: Effect of multivitamins on plasmaney Int 43:1319–1328, 1993
homocysteine and folate levels in patients on hemodialysis. ASAIO7. Makoff R: Vitamin replacement therapy in renal failure patients.
J 45:94–97, 1999Miner Electrolyte Metab 25:349–351, 1999
29. van Guldener C, Janssen MJ, Lambert J, et al: Folic acid treat-8. Leblanc M, Pichette V, Geadah D, Ouimet D: Folic acid and
ment of hyperhomocysteinemia in peritoneal dialysis patients: Nopyridoxal-5-phosphate losses during high-efficiency hemodialysis
change in endothelial function after long-term therapy. Perit Dialin patients without hydrosoluble vitamin supplementation. J Ren
Int 18:282–289, 1998Nutr 10:196–201, 2000
30. Perna AF, Ingrosso D, De Santo NG, et al: Metabolic conse-9. Bostom AG, Shemin D, Bagley P, et al: Controlled comparison
quences of folate-induced reduction of hyperhomocysteinemia inof L-5-methyltetrahydrofolate versus folic acid for the treatment of
uremia. J Am Soc Nephrol 8:1899–1905, 1997hyperhomocysteinemia in hemodialysis patients. Circulation 101:
31. Bostom AG, Shemin D, Lapane KL, et al: High dose B-vitamin2829–2832, 2000
treatment of hyperhomocysteinemia in dialysis patients. Kidney10. Bostom AG, Shemin D, Lapane KL, et al: Folate status is the
Int 49:147–152, 1996major determinant of fasting total plasma homocysteine levels in
32. Thambyrajah J, Landray MJ, McGlynn FJ, et al: Does folic acidmaintenance dialysis patients. Atherosclerosis 123:193–202, 1996
decrease plasma homocysteine and improve endothelial func-11. Robinson K, Gupta A, Dennis V, et al: Hyperhomocysteinemia
tion in patients with predialysis renal failure? Circulation 102:871–confers an independent increased risk of atherosclerosis in end-
875, 2000stage renal disease and is closely linked to plasma folate and pyri-
doxine concentrations. Circulation 94:2743–2748, 1996 33. Jungers P, Joly D, Massy Z, et al: Sustained reduction of hyperho-
De Vriese et al: Effects of folate in renal failure 1209
mocysteinaemia with folic acid supplementation in predialysis pa- drofolate, the active form of folic acid, restores endothelial function
in familial hypercholesterolemia. Circulation 97:237–241, 1998tients. Nephrol Dial Transplant 14:2903–2906, 1999
53. Verhaar MC, Wever RM, Kastelein JJ, et al: Effects of oral folic34. Chauveau P, Chadefaux B, Coude M, et al: Long-term folic
acid supplementation on endothelial function in familial hypercho-acid (but not pyridoxine) supplementation lowers elevated plasma
lesterolemia. A randomized placebo-controlled trial. Circulation 100:homocysteine level in chronic renal failure. Miner Electrolyte Me-
335–338, 1999tab 22:106–109, 1996
54. Wilmink HW, Stroes ES, Erkelens WD, et al: Influence of folic35. Wilcken DE, Dudman NP, Tyrrell PA, Robertson MR: Folic
acid on postprandial endothelial dysfunction. Arterioscler Thrombacid lowers elevated plasma homocysteine in chronic renal insuffi-
Vasc Biol 20:185–188, 2000ciency: Possible implications for prevention of vascular disease.
55. De Vriese AS, Van de Voorde J, Blom HJ, et al: The impairedMetabolism 37:697–701, 1988
renal vasodilator response attributed to endothelium-derived hyper-36. Beaulieu AJ, Gohh RY, Han H, et al: Enhanced reduction of fast-
polarizing factor in streptozotocin-induced diabetic rats is restoreding total homocysteine levels with supraphysiological versus stan-
by 5-methyltetrahydrofolate. Diabetologia 43:1116–1125, 2000dard multivitamin dose folic acid supplementation in renal trans-
56. Usui M, Matsuoka H, Miyazaki H, et al: Endothelial dysfunctionplant recipients. Arterioscler Thromb Vasc Biol 19:2918–2921, 1999
by acute hyperhomocyst(e)inaemia: Restoration by folic acid. Clin37. Bostom AG, Gohh RY, Beaulieu AJ, et al: Treatment of hyperho-
Sci 96:235–239, 1999mocysteinemia in renal transplant recipients. A randomized, pla-
57. Stroes ES, van Faassen EE, Yo M, et al: Folic acid reverts dys-cebo-controlled trial. Ann Intern Med 127:1089–1092, 1997
function of endothelial nitric oxide synthase. Circ Res 86:1129–38. Arnadottir M, Hultberg B: Treatment with high-dose folic acid
1134, 2000effectively lowers plasma homocysteine concentration in cyclospo-
58. Wever R, Boer P, Hijmering M, et al: Nitric oxide production isrine-treated renal transplant recipients. Transplantation 64:1087, 1997
reduced in patients with chronic renal failure. Arterioscler Thromb39. Wilcken DE, Gupta VJ, Betts AK: Homocysteine in the plasma
Vasc Biol 19:1168–1172, 1999of renal transplant recipients: Effects of cofactors for methionine 59. Bellamy MF, McDowell IF, Ramsey MW, et al: Oral folate en-metabolism. Clin Sci Colch 61:743–749, 1981 hances endothelial function in hyperhomocysteinaemic subjects.40. Hong SY, Yang DH, Chang SK: Plasma homocysteine, vitamin Eur J Clin Invest 29:659–662, 1999
B6, vitamin B12 and folic acid in end-stage renal disease during 60. Miyazaki H, Matsuoka H, Itabe H, et al: Hemodialysis impairs
low-dose supplementation with folic acid. Am J Nephrol 18:367– endothelial function via oxidative stress: Effects of vitamin E-coated
372, 1998 dialyzer. Circulation 101:1002–1006, 2000
41. Bostom AG, Shemin D, Nadeau MR, et al: Short term betaine 61. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al: Endothelial
therapy fails to lower elevated fasting total plasma homocysteine dysfunction in diabetes. Br J Pharmacol 130:963–974, 2000
concentrations in hemodialysis patients maintained on chronic folic 62. Dilsizian V: The role of myocardial perfusion imaging in vascular
acid supplementation. Atherosclerosis 113:129–132, 1995 endothelial dysfunction. J Nucl Cardiol 7:180–184, 2000
42. Guttormsen AB, Schneede J, Ueland PM, Refsum H: Kinetics 63. Pancharuniti N, Lewis CA, Sauberlich HE, et al: Plasma homo-
of total plasma homocysteine in subjects with hyperhomocysteine- cyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-
mia due to folate or cobalamin deficiency. Am J Clin Nutr 63:194– onset coronary artery disease. Am J Clin Nutr 59:940–948, 1994
202, 1996 64. Giles WH, Kittner SJ, Anda RF, et al: Serum folate and risk for
43. Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic ischemic stroke. First National Health and Nutrition Examination
basis of hyperhomocysteinemia in patients with chronic renal fail- Survey epidemiologic follow-up study. Stroke 26:1166–1170, 1995
ure. Kidney Int 52:495–502, 1997 65. Loehrer FM, Angst CP, Haefeli WE, et al: Low whole-blood
S-adenosylmethionine and correlation between 5-methyltetrahy-44. van Guldener C, Donker AJ, Jakobs C, et al: No net renal extrac-
drofolate and homocysteine in coronary artery disease. Arteriosclertion of homocysteine in fasting humans. Kidney Int 54:166–169, 1998
Thromb Vasc Biol 16:727–733, 199645. Bostom A, Brosnan JT, Hall B, et al: Net uptake of plasma homo-
66. Morrison HI, Schaubel D, Desmeules M, Wigle DT: Serumcysteine by the rat kidney in vivo. Atherosclerosis 116:59–62, 1995
folate and risk of fatal coronary heart disease. JAMA 275:1893–46. House AA, Wells GA, Donnelly JG, et al: Randomized trial of
1896, 1996high-flux vs low-flux haemodialysis: Effects on homocysteine and
67. Robinson K, Arheart K, Refsum H, et al: Low circulating folatelipids. Nephrol Dial Transplant 15:1029–1034, 2000
and vitamin B6 concentrations: Risk factors for stroke, peripheral47. Van Tellingen A, Grooteman MP, Bartels PC, et al: Long-term
vascular disease, and coronary artery disease. European COMACreduction of plasma homocysteine levels by super-flux dialyzers
Group. Circulation 97:437–443, 1998in hemodialysis patients. Kidney Int 59:342–347, 2001
68. Rimm EB, Willett WC, Hu FB, et al: Folate and vitamin B6 from48. Thambyrajah J, Landray MJ, McGlynn FJ, et al: Abnormalities
diet and supplements in relation to risk of coronary heart diseaseof endothelial function in patients with predialysis renal failure. among women. JAMA 279:359–364, 1998
Heart 83:205–209, 2000 69. Clarke R, Armitage J: Vitamin supplements and cardiovascular
49. Hand MF, Haynes WG, Webb DJ: Hemodialysis and L-arginine, risk: Review of the randomized trials of homocysteine-lowering
but not D-arginine, correct renal failure-associated endothelial vitamin supplements. Semin Thromb Hemost 26:341–348, 2000
dysfunction. Kidney Int 53:1068–1077, 1998 70. Butterworth CE Jr, Tamura T: Folic acid safety and toxicity: A
50. Hausberg M, Kisters K, Kosch M, et al: Flow-mediated vasodila- brief review. Am J Clin Nutr 50:353–358, 1989
tion and distensibility of the brachial artery in renal allograft recipi- 71. Christen WG, Ridker PM: Blood levels of homocysteine and ath-
ents. Kidney Int 55:1104–1110, 1999 erosclerotic vascular disease. Curr Atheroscler Rep 2:194–199, 2000
51. Suwaidi JA, Hamasaki S, Higano ST, et al: Long-term follow- 72. Malinow MR, Bostom AG, Krauss RM: Homocyst(e)ine, diet,
up of patients with mild coronary artery disease and endothelial and cardiovascular diseases: A statement for healthcare profession-
dysfunction. Circulation 101:948–954, 2000 als from the Nutrition Committee, American Heart Association.
Circulation 99:178–182, 199952. Verhaar MC, Wever RM, Kastelein JJ, et al: 5-methyltetrahy-
